Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

Nicola Curtin; Yvette Drew; Sweta Sharma Saha

doi:10.1038/s41571-019-0285-2

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

Nicola Curtin, Yvette Drew, Sweta Sharma Saha

Research output: Contribution to journal › Article › peer-review

Abstract

BRCA1/2 mutations and poly (ADP-ribose) polymerase (PARP) inhibitors are paradigmatic of synthetic lethal therapy. However, the activity of PARP inhibitors seems to vary considerably across BRCA1/2-mutant cancers and new insights into the tumour-lineage dependency of this synthetic lethal relationship might explain why BRCA1/2 mutations are not tumour-agnostic biomarkers of a response to PARP inhibitors.

Original language	English
Pages (from-to)	725–726
Journal	Nature Reviews Clinical Oncology
Volume	16
DOIs	https://doi.org/10.1038/s41571-019-0285-2
Publication status	Published - 3 Oct 2019
Externally published	Yes

Access to Document

10.1038/s41571-019-0285-2

Cite this

@article{3d501a66f7404c7284bc783614eb1a2b,

title = "Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy",

abstract = "BRCA1/2 mutations and poly (ADP-ribose) polymerase (PARP) inhibitors are paradigmatic of synthetic lethal therapy. However, the activity of PARP inhibitors seems to vary considerably across BRCA1/2-mutant cancers and new insights into the tumour-lineage dependency of this synthetic lethal relationship might explain why BRCA1/2 mutations are not tumour-agnostic biomarkers of a response to PARP inhibitors.",

author = "Nicola Curtin and Yvette Drew and \{Sharma Saha\}, Sweta",

year = "2019",

month = oct,

day = "3",

doi = "10.1038/s41571-019-0285-2",

language = "English",

volume = "16",

pages = "725–726",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

AU - Curtin, Nicola

AU - Drew, Yvette

AU - Sharma Saha, Sweta

PY - 2019/10/3

Y1 - 2019/10/3

N2 - BRCA1/2 mutations and poly (ADP-ribose) polymerase (PARP) inhibitors are paradigmatic of synthetic lethal therapy. However, the activity of PARP inhibitors seems to vary considerably across BRCA1/2-mutant cancers and new insights into the tumour-lineage dependency of this synthetic lethal relationship might explain why BRCA1/2 mutations are not tumour-agnostic biomarkers of a response to PARP inhibitors.

AB - BRCA1/2 mutations and poly (ADP-ribose) polymerase (PARP) inhibitors are paradigmatic of synthetic lethal therapy. However, the activity of PARP inhibitors seems to vary considerably across BRCA1/2-mutant cancers and new insights into the tumour-lineage dependency of this synthetic lethal relationship might explain why BRCA1/2 mutations are not tumour-agnostic biomarkers of a response to PARP inhibitors.

UR - http://dx.doi.org/10.1038/s41571-019-0285-2

U2 - 10.1038/s41571-019-0285-2

DO - 10.1038/s41571-019-0285-2

M3 - Article

SN - 1759-4774

VL - 16

SP - 725

EP - 726

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

ER -

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this